Dendrite International, Inc. acquires Optas

BOSTON, MA – September 12, 2005 – Mirus Capital Advisors, Inc., an investment bank specializing in middle-market merger and acquisition advisory services, announced today that it has advised Optas, Inc., on the sale of its business to Dendrite International, Inc. (NASDAQ: DRTE) for $12 million of cash consideration. Under the agreement, the company, a provider of privacy-safe relationship marketing solutions for patients and physicians, becomes a division of Dendrite International, Inc. Located in Bedminster, NJ, Dendrite is a leading provider of sales, marketing, and clinical solutions for the pharmaceutical industry.

“We have no doubt that we made the best possible choice in picking Peter Alternative and the team at Mirus,” said Steve Smith, CEO of Optas. “They very quickly and thoroughly assimilated our business model and put the positioning together. They were bright and hard working and showed very high integrity. I would highly recommend Mirus to other companies.”

According to a press announcement from Dendrite, the resulting integrated patient and prescriber-based marketing programs will enable pharmaceutical companies to reach physicians and consenting patients with consistent messages while maintaining adherence with federal and state regulations surrounding privacy (e.g., HIPAA – the Health Insurance Portability and Accountability Act).

Optas, formerly a private company headquartered in Woburn, MA, will be branded as Optas: a Division of Dendrite International. Founded in 1997, Optas’ leading-edge database marketing software and services allow pharmaceutical companies and health systems to communicate more effectively with customers. Marketers and their agencies use Optas solutions to improve acquisition and loyalty of their customers. Optas provides rapid deployment and a high return on marketing investment for its clients because of its customizable support of business processes.

Founded in 1986, Dendrite International serves the global life sciences and pharmaceutical industry. The firm has clients in more than 50 countries, including the world’s top 20 pharmaceutical companies.

About Mirus Capital Advisors

Mirus Capital Advisors provides investment banking solutions to corporate clients in technology, business services, manufacturing, consumer products, health care, and the resort & hospitality industry. Since 1987, Mirus has provided corporate finance advisory services on engagements including mergers, acquisitions, divestitures, recapitalizations, and valuations. For additional information, visit www.merger.com.